Absolute vs. Relative Bioavailability: Understanding the First-Pass Effect
The Myth of the Swallowed Pill
A 100 mg tablet does NOT equal 100 mg reaching systemic circulation. The journey from stomach to bloodstream is a lethal obstacle course for pharmaceutical molecules.
Bioavailability (F) quantifies the fraction of a drug that physically survives to enter systemic circulation.
Absolute Bioavailability
The gold standard benchmark — comparing an extravascular dose against IV delivery (
If
Relative Bioavailability
Compares two extravascular formulations against each other — the basis for generic drug certification (bioequivalence studies).
The Three Horsemen of Extravascular Destruction
Disintegration & Dissolution
If a hydrophobic drug fails to dissolve in gastric juices, it transits the entire GI tract intact — zero absorption. This is purely a formulation engineering failure.
Enterocyte Membrane Impermeability
Dissolved drug molecules must penetrate the intestinal cell membrane. Barriers include:
- Bulky molecules (proteins, mAbs) cannot squeeze through
- Efflux pumps (P-glycoprotein) actively eject drug back into the lumen
The Hepatic First-Pass Effect
This is the most critical hurdle in oral pharmacokinetics.
Portal vein blood routes through the liver before reaching systemic circulation. CYP450 enzymes in the liver metabolize susceptible drugs during this first pass.
Classic Example: Lidocaine — undergoes such devastating first-pass metabolism that oral dosing yields virtually 0% bioavailability. This forces IV, dermal, or IM delivery routes.
Predicting First-Pass Failure
Factor bioavailability into your study design:
| Bioavailability | Interpretation |
|---|---|
| F > 0.7 | High — oral dosing viable |
| F = 0.3–0.7 | Moderate — dose adjustment needed |
| F < 0.3 | Low — consider alternative routes |
| F ≈ 0 | IV/IM/SC only (e.g., Lidocaine, insulin) |
Try It on Pharazi.ai
Calculate bioavailability from IV and oral exposure data using the Absolute Bioavailability Calculator.
References
- Rowland M, Tozer TN. Clinical Pharmacokinetics. 4th ed.
- FDA. Guidance for Industry: Bioavailability Studies. 2014.
Related Articles
Linear vs. Non-Linear Pharmacokinetics: Michaelis-Menten Explained
Explore the critical threshold where linear PK mathematics fail. Understand Michaelis-Menten kinetics, zero-order elimination, and drugs with unpredictable half-lives.
PK BasicsMastering Non-Compartmental Analysis (NCA): Key Parameters Explained
Learn the fundamentals of NCA, the gold standard PK methodology for deriving AUC, Cmax, clearance, and volume of distribution.